These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406 [TBL] [Abstract][Full Text] [Related]
5. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106 [TBL] [Abstract][Full Text] [Related]
7. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities. Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504 [TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
11. Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes. Aydh A; Sari Motlagh R; Alamri A; Yanagisawa T; Ayed A; Rajwa P; Laukhtina E; Alasiri SM; Kawada T; Mostafai H; Ayidh A; Pallauf M; König F; Abufaraj M; Karakiewicz PI; Shariat SF World J Urol; 2023 Aug; 41(8):2185-2194. PubMed ID: 37347252 [TBL] [Abstract][Full Text] [Related]
12. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
15. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500 [TBL] [Abstract][Full Text] [Related]
16. Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis. Yu C; Hequn C; Jinbo C; Feng Z; Xiongbing Z; Jian D J Cancer Res Ther; 2018; 14(6):1260-1265. PubMed ID: 30488841 [TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Pal SK; Ruel NH; Wilson TG; Yuh BE Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR; Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323 [TBL] [Abstract][Full Text] [Related]
19. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer]. Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer. Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG Oncology; 2017; 93(1):36-42. PubMed ID: 28399521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]